Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy volunteers

European Neurology

Volumn 49, Issue 1, 2003, Pages 39-44

  Crevoisier, C ^a,b   Monreal, A ^c   Metzger, B ^c   Nilsen, T ^d  

^a Clinical Pharmacology Services   (Switzerland)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c FORENAP   (France)

^d Bioanalytica   (Norway)

Author keywords

Bioavailability; Dual release; Levodopa; Multiple dose; Parkinson's disease; Pharmacokinetics

Indexed keywords

3 O METHYLDOPA; BENSERAZIDE PLUS LEVODOPA; LEVODOPA;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG FORMULATION; DRUG RELEASE; DRUG SAFETY; DRUG SCREENING; FEMALE; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; VERTIGO;

ADULT; ANTIPARKINSON AGENTS; BENSERAZIDE; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DOPAMINE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; HUMANS; LEVODOPA; MALE; METHYLDOPA; REFERENCE VALUES;

EID: 0037216186     PISSN: 00143022     EISSN: None     Source Type: Journal    
DOI: 10.1159/000067025     Document Type: Article

References (27)

1. Marsden CD: Parkinson's disease. Lancet 1990;335:948-952
2. Shoulson I, Glaubiger GA, Chase TN: On-off response: Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology 1975;25:1144-1148.
3. Kempster PA, Frankel JP, Bovingdon M, Webster R, Lees AJ, Stern GM: Levodopa peripheral pharmacokinetics and duration of motor response in Parkinson's disease. J Neurol Neurosurg Psychiatry 1989;52:718-723.
4. Nutt JG, Woodward WR: Levodopa pharmacokinetics and pharmacodynamics in fluctuating parkinsonian patients. Neurology 1986;36:739-744.
5. Gancher ST, Nutt JG, Woodward WR: Peripheral pharmacokinetics of levodopa in untreated, stable and fluctuating parkinsonian patients. Neurology 1987;37:940-944.
6. Mena I, Cotzias C: Protein intake and treatment of Parkinson's disease with levodopa. N Engl J Med 1975;292:181-184.
7. Obeso JA, Vaamonde J, Grandas F, Luquin MR, Rodriguez M, Lera G, Martinez-Lage JM: Overcoming pharmacokinetic problems in the treatment of Parkinson's disease. Mov Disord 1989;4(suppl 1):S70-S85.
8. Tolosa ES, Valldeoriola F, Marti MJ: New and emerging strategies for improving levodopa treatment. Neurology 1994;44 (suppl 6):35-44.
9. Crevoisier C, Hoevels B, Zürcher G, Da Prada M: Bioavailability of L-Dopa after Madopar HBS administration in healthy volunteers. Eur Neurol 1987;27(suppl 1):36-46.
10. Yeh KC, August TF, Bush DF, Lasseter KC, Musson DG, Schwartz S, Smith ME, Titus DC: Pharmacokinetics and bioavailability of Sinemet CR: A summary of human studies. Neurology 1989;39(suppl 2):25-38.
11. Ceballos AO, von Kummer R, Eckert W, Weicker H: Controlled-release levodopa/benserazide (Madopar HBS): Clinical observations and levodopa and dopamine plasma concentrations in fluctuating parkinsonian patients. J Neurol 1990;237:24-28.
12. Poewe WH, Lees AJ, Stern GM: Treatment of motor fluctuations in Parkinson's disease with an oral sustained-release preparation of L-Dopa: Clinical and pharmacokinetic observations. Clin Neuropharmacol 1986;9:430-439.
13. Gibaldi M, Perrier D: Pharmacokinetics, Ed 2. New York, Dekker, 1982.
14. Schuirman DJ: A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence and average bio-availability. J Pharmacokinet Biopharm 1987; 15:657-680.
15. Committee for Proprietary Medicinal Products (CPMP): Working Party on the Efficacy of Medicinal Products 1991. Note for Guidance: Investigation of Bioavailability and Bioequivalence. London, EMEA, 1991.
16. Contin M, Riva R, Martinelli P, Cortelli P, Albani F, Baruzzi A: Pharmacodynamic modeling of oral levodopa: Clinical application in Parkinson's disease. Neurology 1993;43:367-371.
17. Grahnen A, Eckernäs SA, Collin C, Ling-Andersson A, Tiger G, Nilsson M: Comparative multiple-dose pharmacokinetics of controlled-release levodopa products. Eur Neurol 1992;32:343-348.
18. Dingemanse J, Kleinbloesem CH, Zürcher G, Wood ND, Crevoisier C: Pharmacodynamics of benserazide assessed by its effects on endogenous and exogenous levodopa pharmacokinetics. Br J Clin Pharmacol 1997;44:41-48.
19. Gasser UE, Jorga K, Crevoisier C, Hovens SEL, van Giersbergen PLM: COMT inhibition by tolcapone further improves levodopa pharmacokinetics when combined with a dual-release formulation of levodopa/benserazide. Eur Neurol 1999;41:206-211.
20. Erni W, Held K: The hydrodynamically balanced system: A novel principle of controlled release. Eur Neurol 1987;27(suppl 1):21-27.
21. Cedarbaum JM: Clinical pharmacokinetics of anti-parkinsonian drugs. Clin Pharmacokinet 1987;13:141-178.
22. Wade LA, Katzman R: 3-O-methyldopa uptake and inhibition of L-Dopa at the blood-brain barrier. Life Sci 1975;17:131-136.
23. Nutt JG, Woodward WR, Gancher ST, Merrick D: 3-O-methyldopa and the response to levodopa in Parkinson's disease. Ann Neurol 1987;21:584-588.
24. Cedarbaum JM, Kutt H, McDowell FH: Clinical significance of the relationship between O-methyldopa levels and levodopa intake. Neurology 1988;38:533-536.
25. Guttman M, Léger G, Cedarbaum JM: 3-O-methyldopa administration does not alter fluorodopa transport into the brain. Ann Neurol 1992;31:638-643.
26. Mena MA, Muradas V, Bazan E, Reiriz J, de Yebenes JG: Pharmacokinetics of L-Dopa in patients with Parkinson's Disease; in Yahr MD, Bergmann KJ (eds): Advances in Neurology: Parkinson's disease. New York, Raven Press, 1986, vol 45, pp 481-486.
27. Gasser UE, Crevoisier C, Ouwerkerk M, Lankhaar G, Dingemanse J: Comparative single-and multipledose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and conventional slow-release formulation of levodopa and benserazide in healthy subjects. Eur J Pharm Biopharm 1998;46:223-228.